FDA Approves First Brain-Penetrating Enzyme Therapy for Hunter Syndrome
Denali's Avlayah uses a novel transport platform to cross the blood-brain barrier, cutting CSF biomarkers by 91% in trials.
Summary
The FDA has approved Avlayah, a first-of-its-kind enzyme replacement therapy that can penetrate the brain to treat Hunter syndrome in children. Developed by Denali Therapeutics, the drug uses a transferrin receptor-based delivery system to cross the blood-brain barrier — a longstanding obstacle in neurology. In Phase 1/2 trials, it reduced a key brain biomarker called heparan sulfate by 91% within 24 weeks, with 93% of patients reaching normal levels. This accelerated approval marks a milestone not just for a rare pediatric disease, but for the broader field of brain-targeted drug delivery, which has implications for Alzheimer's, Parkinson's, and other neurological conditions affecting aging adults.
Detailed Summary
The FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) on March 25, 2026, represents a landmark moment in neuroscience and drug delivery. Hunter syndrome, a rare genetic disorder caused by a missing enzyme, leads to toxic buildup of heparan sulfate in the brain and body. Until now, no therapy could meaningfully address the neurological damage because the blood-brain barrier blocked enzyme replacement drugs from reaching the brain.
Denali Therapeutics solved this with its TransportVehicle platform, which attaches the therapeutic enzyme to a molecule that hijacks the brain's own transferrin receptor transport system. This allows the drug to be actively shuttled across the blood-brain barrier — a strategy with enormous potential implications beyond Hunter syndrome.
The clinical data supporting approval are striking. In Phase 1/2 trials, Avlayah reduced cerebrospinal fluid heparan sulfate levels by 91% at 24 weeks, and 93% of treated patients achieved full normalization of this biomarker. These are meaningful biological signals, though the accelerated approval pathway means confirmatory evidence from the ongoing Phase 2/3 COMPASS trial is still required.
For the longevity and brain health community, the significance extends well beyond a rare pediatric disease. The transferrin receptor transcytosis mechanism Denali has validated could serve as a blueprint for delivering other therapeutics — including those targeting amyloid, tau, or neuroinflammation — directly into the brain. This is a delivery problem that has stalled countless Alzheimer's and Parkinson's drug programs for decades.
Caveats remain: this is an accelerated approval based on a biomarker surrogate endpoint, not confirmed clinical outcomes. The patient population is pediatric and rare, so extrapolation to adult neurodegeneration requires caution. Still, the platform validation is a genuine scientific advance worth watching closely as broader applications are explored.
Key Findings
- Avlayah reduced brain heparan sulfate by 91% at 24 weeks in Phase 1/2 trials.
- 93% of treated pediatric patients achieved full normalization of CSF heparan sulfate levels.
- Denali's TransportVehicle platform crosses the blood-brain barrier via transferrin receptor transcytosis.
- This is the first FDA-approved brain-penetrating biologic, setting a precedent for neurological drug delivery.
- Approval is accelerated; confirmatory Phase 2/3 COMPASS trial data are still required.
Methodology
This is a news report summarizing an FDA approval announcement and associated Phase 1/2 clinical trial data. The source, Longevity.Technology, is a credible longevity-focused outlet. Evidence is based on regulatory approval documents and company-reported trial results, not yet peer-reviewed in full.
Study Limitations
Approval is accelerated and based on a biomarker surrogate endpoint rather than confirmed functional or cognitive outcomes. The trial population is small and pediatric, limiting direct extrapolation to adult neurodegeneration. Full Phase 2/3 confirmatory data and peer-reviewed publications should be reviewed before drawing broader conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.